Share on StockTwits

Epizyme (NASDAQ:EPZM) EVP Robert A. Copeland sold 25,012 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $26.38, for a total transaction of $659,816.56. Following the transaction, the executive vice president now directly owns 5,305 shares in the company, valued at approximately $139,946. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Epizyme (NASDAQ:EPZM) traded up 3.40% on Wednesday, hitting $29.47. 343,466 shares of the company’s stock traded hands. Epizyme has a 52 week low of $18.10 and a 52 week high of $45.72. The stock has a 50-day moving average of $23.2 and a 200-day moving average of $25.87. The company’s market cap is $969.1 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.25. On average, analysts predict that Epizyme will post $-1.78 earnings per share for the current fiscal year.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.